Newsroom

Company news

Business
06 July 2021

Alvotech initiates clinical studies for AVT04, a proposed biosimilar to Stelara® (ustekinumab)

People
28 June 2021

Create your own future - Is your future in biosimilars?

Business
25 June 2021

Alvotech bondholders convert more than $100m at pre-money valuation of $2.7bn

Business
15 June 2021

Alvotech reaches primary completion date in its switching study for AVT02, a proposed interchangeable biosimilar to AbbVie's Humira®

Business
08 June 2021

Robert Wessman presented at the Jefferies Global Healthcare Conference

Charity
07 June 2021

Alvotech employees donate to UNICEF Covid relief in India

Business
11 May 2021

Alvotech seeks to end AbbVie’s wrongful monopoly on Humira and bring affordable arthritis treatment to U.S.

Charity
10 May 2021

Alvotech proud sponsor of Reykjavik’s football club KR

Business
25 March 2021

Alvotech disputes AbbVie’s allegations of wrongdoing

Business
15 March 2021

Alvotech completes second round of a US$ 100m private placement

Charity
05 March 2021

Alvotech and sister company Alvogen donate 100 thousand US dollars to UNICEF in combat against COVID-19

Business
02 March 2021

Cipla Gulf and Alvotech expand partnership for commercialization of biosimilars in Australia and New Zealand

Business
25 February 2021

Alvotech Iceland receives Equal Pay Certification

Business
30 December 2020

Ground-breaking for the extension of Alvotech's high-tech centre in Reykjavik

Business
10 December 2020

Alvotech and Fuji Pharma extend biosimilar partnership in Japan

Business
24 November 2020

Alvotech, Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical agree on an exclusive biosimilar partnership in China

Business
19 November 2020

Alvotech announces that the U.S. FDA and EMA have accepted regulatory submissions for AVT02, a proposed biosimilar to Humira® (adalimumab)

Business
04 November 2020

Alvotech and Cipla partner to ensure access to biosimilars in South Africa

Business
27 October 2020

Alvotech announces private placement financing

Media Contact

Elisabet Hjaltadottir

Corporate Marketing & Communication